Nadolol
Nadolol
Definition
A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention.
Also known as Corgard, NADOLOL — per NCIT
Also identified as
- ATC C07AA12 per RXNORM
- NCIT NCIT:C29280 per NCIT
- SCTID 387482003 per RXNORM
- SCTID 82896009 per RXNORM
- UNII FEN504330V per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Heart failure | may treat | MEDRT · Public domain (U.S. Government work) |
| Hypertensive disorder | may treat | MEDRT · Public domain (U.S. Government work) |
| Myocardial infarction | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Heart | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Myocardium | may treat a disease of this organ | DERIVED · CC BY 4.0 |
5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.